By Dr. John L. Ferrell III, M.D.(*)
⚡ Clinical Insight: The Truth About Insurance
If you’ve been told treatments like PRP or MFAT are “experimental,” here is what the insurance companies aren’t telling you:
- It’s Not a Data Issue: There are numerous Level 1 Research Studies proving the efficacy of regenerative medicine for tendons and joints.
- The Patent Problem: Because we use your own biology, no corporation can “own” the treatment, which stalls the traditional FDA drug-approval path.
- Bridging the Gap: While major carriers lag behind, third-party companies are often helping patients access these life-changing procedures.
- Our Commitment: At ROSM, we lead the way in ongoing research to move the needle on national advocacy and care standards.
If you’ve been struggling with chronic tendonitis, a ligament tear, or the grinding pain of osteoarthritis, you’ve likely heard about the promise of regenerative medicine. Treatments like Platelet-Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), and Autologous Microfragmented Adipose Injections (MFAT) are changing lives by slowing disease progression and restoring function without the need for invasive surgery.
Yet, when you call your insurance provider, you’re almost always met with the same word: “Experimental.”
Most patients assume this means there isn’t enough data. But at ROSM, we know that simply isn’t the case. Our team specializes in Platelet-Rich Plasma (PRP) and other advanced therapies that use your body’s own healing potential. Here is the real reason the system is lagging behind the science.
It’s Not a Lack of Data, It’s a Lack of a Patent
The gold standard for medical evidence is the Level 1 Research Study. Today, the science is clear: PRP and other orthobiologics are highly effective for various orthopedic conditions. However, the insurance “machinery” requires a specific stamp: FDA Drug Approval.
To get a treatment through the FDA’s clinical trials typically requires a massive financial investment, often reaching between $50 million and $100 million.
- With Synthetic Drugs: A pharmaceutical company spends that money because they can patent a chemical formula and have exclusive rights to sell it.
- With Regenerative Medicine: We are using your own blood and your own cells to heal you. You cannot patent a human being’s natural biology.
Because no single corporation can “own” the rights to your cells, the traditional drug-protocol hurdles remain difficult to clear. Without that specific FDA “drug” label, major insurance carriers continue to hide behind the “experimental” tag to avoid payouts. We discussed similar hurdles in our previous guide on whether you can truly “cure” knee arthritis through joint preservation.
The Cost of Innovation
While we are seeing progress, including new data on how PRP and MFAT help even severe arthritis cases, major medical coverage is still catching up. In the meantime, patients at ROSM are finding alternative ways to access care:
- Third-Party Support: Some companies have begun reimbursing patients for regenerative treatments, helping bridge the gap traditional insurance leaves behind.
- Advocacy: We encourage patients to keep the pressure on by asking providers for detailed explanations of why they ignore Level 1 data.
The ROSM Commitment: Leading the Revolution
At ROSM, we refuse to let the “patent problem” stop us from providing the best possible care. We believe you shouldn’t have to wait a decade for the system to catch up to the science.
We remain dedicated to:
- Participating in Groundbreaking Research: We don’t just read the studies; we lead them, including our ongoing MFAT research studies for partial rotator cuff tears.
- Holistic Integration: We focus on the whole kinetic chain rather than just “masking” symptoms with pills or cortisone.
The biological revolution is here, even if the insurance companies haven’t checked their mail yet.
Ready to walk a new path to healing? Schedule a consultation at one of our locations in DC, Maryland, or Virginia.
